The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 27, 2025

Filed:

Sep. 16, 2019
Applicant:

China Pharmaceutical University, Nanjing, CN;

Inventors:

Haopeng Sun, Nanjing, CN;

Hongyu Yang, Nanjing, CN;

Tingkai Chen, Nanjing, CN;

Yao Chen, Nanjing, CN;

Feng Feng, Nanjing, CN;

Chenxi Du, Nanjing, CN;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/381 (2006.01); A61K 31/167 (2006.01); A61K 31/195 (2006.01); A61K 31/24 (2006.01); A61K 31/277 (2006.01); A61K 31/341 (2006.01); A61K 31/40 (2006.01); A61K 31/4164 (2006.01); A61K 31/426 (2006.01); A61K 31/4402 (2006.01); A61P 25/28 (2006.01);
U.S. Cl.
CPC ...
A61K 31/381 (2013.01); A61K 31/167 (2013.01); A61K 31/195 (2013.01); A61K 31/24 (2013.01); A61K 31/277 (2013.01); A61K 31/341 (2013.01); A61K 31/40 (2013.01); A61K 31/4164 (2013.01); A61K 31/426 (2013.01); A61K 31/4402 (2013.01); A61P 25/28 (2018.01);
Abstract

The present invention discloses a selective butyrylcholinesterase inhibitor having a general formula (I) or a pharmaceutically acceptable salt thereof, a preparation method and use thereof. The treatment efficacy of Alzheimer's disease, especially moderate to severe Alzheimer's disease, is tested through butyrylcholinesterase inhibitory activity, selectivity screening and toxicity to nerve cells as a carrier, and it is found that it has good target activity in vitro, extremely high selectivity and drug safety, can be used as a lead substance for further development of the treatment of Alzheimer's disease by selectively inhibiting butyrylcholinesterase.


Find Patent Forward Citations

Loading…